RICCIARDI, GIUSEPPINA ROSARIA
 Distribuzione geografica
Continente #
EU - Europa 641
NA - Nord America 529
AS - Asia 111
Totale 1281
Nazione #
US - Stati Uniti d'America 529
IE - Irlanda 213
SE - Svezia 169
CN - Cina 102
IT - Italia 66
AT - Austria 30
PL - Polonia 28
BE - Belgio 26
FI - Finlandia 24
FR - Francia 23
DE - Germania 20
GB - Regno Unito 20
UA - Ucraina 20
VN - Vietnam 5
IR - Iran 2
IN - India 1
JP - Giappone 1
RO - Romania 1
RU - Federazione Russa 1
Totale 1281
Città #
Dublin 213
Chandler 159
Nyköping 86
Jacksonville 54
Ann Arbor 52
Beijing 48
Warsaw 28
Brussels 26
Messina 26
Vienna 26
Princeton 25
Medford 24
Cambridge 23
Dearborn 18
Des Moines 18
Boardman 13
Woodbridge 12
Jinan 9
Lancaster 8
Nanjing 8
San Mateo 8
Tianjin 6
Wilmington 6
Dong Ket 5
Hangzhou 4
Hebei 4
Leawood 4
Bremen 3
Fuzhou 3
Jiaxing 3
Nanchang 3
Ningbo 3
Shenyang 3
Trepuzzi 3
Catania 2
Grammichele 2
Lissone 2
Monmouth Junction 2
Taizhou 2
Zhengzhou 2
Acireale 1
Ardabil 1
Cannock 1
Changsha 1
Fort Washington 1
Guangzhou 1
Haikou 1
Helsinki 1
Hendon 1
Houston 1
Iasi 1
Milan 1
Norwalk 1
Philadelphia 1
Rüsselsheim 1
Simi Valley 1
Tehran 1
Wenzhou 1
Totale 964
Nome #
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 95
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 80
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 75
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 73
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 65
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications. 65
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 65
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 58
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 53
null 52
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 52
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives. 51
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 50
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 49
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 46
Correlation between serum magnesium levels and skin toxicity during cetuximab treatment in squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. 43
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 41
Observational study to evaluate the pattern of trastuzumab (T) use and survival outcomes in HER2-positive (HER2+) early breast cancer (EBC): Regional Southern Italy experience. 41
Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient 41
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 40
Infra-centimetric HER2 positive Breast Cancer: The Southern Italy Experience. 39
Multicenter study in women with infracentimetric HER2 positive breast cancer: The Regional Sicilian experience. 38
Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience. 31
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 31
null 22
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 14
Totale 1310
Categoria #
all - tutte 2620
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2620


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201823 0000 00 00 00230
2018/201933 0000 126 13 4106
2019/2020152 12242 022 1817 636267
2020/2021200 1603324 1818 137 11222513
2021/2022189 32155 34 106 3472359
2022/2023609 39612145 4763 1138 269690
Totale 1310